Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1)
arcticnovartis
Tue, 09/08/2026 – 07:04
Read more about Novartis provides update on delpacibart etedesiran …
Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
arcticnovartis
Fri, 09/04/2026 – 22:34
Read more about Novartis announces Lp(a)HORIZON Phase III …
Novartis remibrutinib, a high-efficacy oral BTK inhibitor, significantly reduces relapse rates and shows favorable safety profile in Phase III RMS trials
arcticnovartis
Tue, 09/01/2026 – 07:17
Read more about Novartis remibrutinib, a high-efficacy…
Novartis data at ESC Congress 2026 reinforce cardiovascular leadership and showcase progress in next-generation therapies
arcticnovartis
Wed, 08/19/2026 – 07:19
Read more about Novartis data at ESC Congress 2026 reinforce cardiovascular leadership…
Novartis data at ESC Congress 2026 reinforce cardiovascular leadership and showcase progress in next-generation therapies
arcticnovartis
Wed, 08/19/2026 – 07:19
Read more about Novartis data at ESC Congress 2026 reinforce cardiovascular leadership…
FDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease
arcticnovartis
Fri, 07/31/2026 – 22:29
Read more about FDA approves Pluvicto for PSMA+ metasta…
Novartis verzeichnete im zweiten Quartal Umsatzsteigerungen und baute die Pipeline weiter aus; Prognose für das Geschäftsjahr bekräftigt
arcticnovartis
Tue, 07/21/2026 – 07:03
Read more about Novartis verzeichnete im zweiten Quartal Umsatzsteigeru…
Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed
arcticnovartis
Tue, 07/21/2026 – 07:02
Read more about Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidan…
Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
arcticnovartis
Fri, 07/17/2026 – 01:19
Read more about Novartis Fabhalta® (iptaco…
Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
arcticnovartis
Fri, 07/17/2026 – 01:19
Read more about Novartis Fabhalta® (iptaco…